Company Profiles

driven by the PitchBook Platform

Celentyx

Celentyx
PRIVATE STATUS
11-20 EMPLOYEES
Early Stage VC LATEST DEAL TYPE
$121K LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of healthcare platform designed to understand the effect of small molecule and biological candidate upon the human immune system. The company's ImmuKnowlogy platform allows rapid analysis of drug action on human immune cells and supports early progression of immuno-oncology therapies, enabling physicians to detect human system at the highest levels of resolution.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
Birmingham Research Park
Vincent Drive, Edgbaston
Birmingham B15 2SQ
England

+44 0121 000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Celentyx’s full profile, request a free trial.

Celentyx Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 12-Dec-2007 $121K 00000 00.000 Completed Startup
1. Grant 13-Dec-2006 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Celentyx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Ordinary 1 000 0000.0 0000.0 00 0000.0 0.000
Ordinary 00 00000.0 00000.0 00 00000.0 0.00
To view this company’s complete Cap Table, request access »

Celentyx Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Mercia Technologies Venture Capital Minority 000 0000 000000 0
Spinner Matched Investment Fund Other Minority 000 0000 000000 0
West Midlands Enterprise Venture Capital Minority 000 0000 000000 0

Celentyx Executive Team (7)

Name Title Board
Seat
Contact
Info
Nicholas Barnes Ph.D Co-Founder, Chief Executive Officer & Board Member
Catherine Brady Chief Operating Officer
John Curnow Chief Technology Officer
John Gordon Co-Founder, Chief Scientific Officer & Board Member
Matthew Baker Ph.D Vice President, Immunology and Oncology

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

Celentyx Board Members (5)

Name Representing Role Since Contact
Info
Alan Boyd MD Self Board Member 000 0000
Mark Payton Ph.D Mercia Technologies Board Observer 000 0000
Stephen Ellis Ph.D Celentyx Board Observer 000 0000

2 Former Board Members

You’re viewing 3 of 5 board members. Get the full list »
Questions or concerns about this profile? Reach out to website-support@pitchbook.com